After years of anecdotes and speculation, harm reduction and pharma watchdog advocates have data to back claims that the spike in opioid deaths in the U.S. can be tied to pharmaceutical companies marketing highly addictive opioids to doctors.
Cholesterol guidelines may underestimate statin value; shifting from Ryan White CARE Act to Affordable Care Act coverage; HCV seroconversion and CD4 count suppression; HCV reinfection odds by risk group.
The benefits of pre-pregnancy HIV treatment initiation for mothers-to-be; HIV diagnoses rise among young U.S. MSM; cost effectiveness of PrEP for heterosexual women; methotrexate and arterial function.
A report on HIV patients is one example showing that though the state is often a national beacon in health care, some of its innovations fall short of expectations.
With Only 15% of Diagnosed HCV Patients Receiving Treatment, the Non-Profit I-MAK Hopes to Shift the National Conversation on Drug Pricing
The Initiative for Medicines, Access and Knowledge, Inc. (I-MAK) argues that the high price of hepatitis C cure medicines places them out of reach for most people.
Reductions in erectile function among men who have sex with men; Australia, San Francisco, and 90-90-90 “fast track” targets; hepatitis C infection and HIV risk; safety of the live herpes zoster vaccine.
The Fair Pricing Coalition is working with pharmaceutical companies to ensure fair prices for new HIV drugs on par with those of older medications.
The lack of Medicaid expansion in the South is creating worse racial disparities in the U.S., according to researchers and medical providers discussing the HIV care cascade at CROI 2018.
With Louisiana being the only state in the Deep South that has expanded Medicaid to date, are "End the Epidemic" strategies realistic in the southern U.S.?
If you are living with HIV or AIDS in the U.S., you might be eligible for financial aid. The Social Security Administration offers monthly disability benefits for people in need.